Summary
The 8-week data from the first phase 3 trial (SAPPHIRE) in treating macular edema due to retinal vein occlusion is expected in Q4 (a big binary event for the stock).
Based on the borderline statistical significance in the phase 2 trial, I consider it a low probability that the SAPPHIRE phase 3 trial will be successful.
Is the stock a buy, sell or hold?
Members of our private investing community, Vasuda Healthcare Analytics, get our best ideas and insights. Get started today >>
Clearside Biomedical (NASDAQ:CLSD) was founded in 2011 and is based in Alpharetta, Georgia.
(Source: Finviz)
The company is developing triamcinolone acetonide (TCA), CLS-TA (a corticosteroid) injection administered in the suprachoroidal space of the eye in various eye conditions. Compared to the intravitreal injections, administering the steroid in the suprachoroidal space has the potential for fewer side effects like an increase in eye pressure and increased bioavailability at the intended site.
